V
Valina L. Dawson
Researcher at Johns Hopkins University School of Medicine
Publications - 477
Citations - 88024
Valina L. Dawson is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Neurodegeneration & Parkin. The author has an hindex of 136, co-authored 451 publications receiving 76986 citations. Previous affiliations of Valina L. Dawson include University of Baltimore & Hospital of the University of Pennsylvania.
Papers
More filters
Patent
Lrrk2-mediated neuronal toxicity
TL;DR: In this article, in vitro and in vivo models of leucine-rich repeat kinase-2 (LRRK2) induced neurodegeneration were identified and shown to be kinase dependent.
Journal ArticleDOI
Lymphocyte Activation Gene 3 (Lag3) Contributes to α-Synucleinopathy in α-Synuclein Transgenic Mice.
Hao Gu,Xiuli Yang,Xiaobo Mao,Enquan Xu,Chen Qi,Haibo Wang,Saurav Brahmachari,Bethany York,Manjari Sriparna,Amanda Li,Michael C. Chang,Pavan Patel,Valina L. Dawson,Ted M. Dawson +13 more
TL;DR: Results show that Lag3 contributes to the pathogenesis in the α-syn A53T transgenic mouse model, which significantly delays disease progression and reduces the behavioral deficits in hA53TTransgenic mice leading to prolonged survival.
Book ChapterDOI
PARP and the Release of Apoptosis-Inducing Factor from Mitochondria
TL;DR: This chapter speculated that the PARP-mediated depletion of NAD and ATP or novel signals from PARP over activation might trigger AIF translocation and the authentic factors and the legitimate mechanism of mitochondrial AIF release remain to be explored.
Journal ArticleDOI
Parkin: clinical aspects and neurobiology
TL;DR: Clinical and neuropathological features of Parkinson's disease caused by parkin mutations are reviewed and the emerging evidence that parkin is an E3 ubiquitin-protein ligase and how derangements in its E3 ligase activity might cause autosomal recessive PD is discussed.
Journal ArticleDOI
Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel
George K.E. Umanah,Marco Pignatelli,Xiling Yin,Rong Chen,Joshua Crawford,Stewart Neifert,Leslie A. Scarffe,Adam A. Behensky,Noah Guiberson,Melissa Chang,Erica Ma,Jin Wan Kim,Cibele Canal Castro,Cibele Canal Castro,Xiaobo Mao,Li Chen,Shaida A. Andrabi,Mikhail V. Pletnikov,Ann E. Pulver,Dimitrios Avramopoulos,Antonello Bonci,Antonello Bonci,David Valle,Ted M. Dawson,Valina L. Dawson +24 more
TL;DR: Rare variants in the enzyme Thorase increase AMPAR expression, resulting in behavioral abnormalities in mice that can be rescued with Perampanel, a U.S. Food and Drug Administration–approved drug that may be useful for treating disorders involving compromised AMPAR-mediated glutamatergic neurotransmission.